Novel Therapeutic Applications of Cell-Penetrating Peptide-XIAP-BIR3 Conjugates

This inventive concept expands the scope of cell-penetrating peptide-XIAP-BIR3 conjugates to treat various neurological disorders, including chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, and glioblastoma.

The original patent focused on ocular delivery of cell-penetrating therapeutics for retinal edema treatment. However, the core technology has broader potential applications. This inventive concept addresses the need for effective treatments for neurological disorders, leveraging the XIAP-BIR3 conjugate's ability to inhibit apoptosis and promote cellular survival.

The new claims describe novel therapeutic applications of cell-penetrating peptide-XIAP-BIR3 conjugates. For instance, claim 1 proposes a system for treating CTE by administering the conjugate to the patient. Claim 2 outlines a method for preventing Alzheimer's disease by administering a prophylactic amount of the conjugate. Claim 3 describes a composition for treating Parkinson's disease using a sustained-release formulation. Claim 4 details a device for delivering the conjugate to the patient's brain using a micro-electromechanical systems (MEMS) device. Claim 5 proposes a method for treating glioblastoma by targeting the conjugate to glioblastoma cells using a glioblastoma-specific antibody.

The new claims introduce novel therapeutic applications of cell-penetrating peptide-XIAP-BIR3 conjugates, expanding the technology's scope beyond ocular delivery and retinal edema treatment. The inventive step lies in recognizing the conjugate's potential to address various neurological disorders, and developing new methods, systems, and compositions to achieve this.

Alternative embodiments may include using different cell-penetrating peptides, varying the XIAP-BIR3 conjugate's composition, or exploring other delivery methods, such as nanoparticles or viral vectors. Variations could also involve targeting specific cell types or tissues within the brain.

This inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of neurological disorders. The target market includes companies developing treatments for CTE, Alzheimer's disease, Parkinson's disease, and glioblastoma, as well as research institutions and hospitals.